HCV versus HIV drug discovery: Deja vu all over again?

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

卷:23

Article

Watkins, William J.¹  Desai, Manoj C.¹ 

[1] Gilead Sci Inc, Foster City, CA 94404 USA

关键词: HIV;    HCV;    Antivirals;    Clinical development;    Combination therapy;    Single tablet regimen;    Protease;    Integrase;    Polymerase;    NS3;    NS5A;    Nucleoside;    Non-nucleoside;    NNI;    CCR5;   

DOI  :  10.1016/j.bmcl.2013.02.070

来源: Elsevier

【 摘 要 】

Efforts to address HIV infection have been highly successful, enabling chronic suppression of viral replication with once-daily regimens. More recent research into HCV therapeutics have also resulted in very promising clinical candidates. This Digest explores similarities and differences in the two fields and compares the chronology of drug discovery relative to the availability of enabling tools, and concludes that safe and convenient, once-daily regimens are likely to reach approval much more rapidly for HCV than was the case for HIV. (C) 2013 Elsevier Ltd. All rights reserved.

【 授权许可】

Free